Susquehanna Fundamental Investments’s C4 Therapeutics CCCC Stock Holding History

Susquehanna Fundamental Investments’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$87.8K	Buy	+18,800	New	+$64.3K	﹤0.01%	725
2026 Q1	–	Sell	-67,617	Closed	-$129K	–	518
2025 Q4	$129K	Hold	67,617	–	–	﹤0.01%	529
2025 Q3	$150K	Hold	67,617	–	–	0.01%	525
2025 Q2	$96.7K	Sell	67,617 -144,386	-68%	-$210K	﹤0.01%	698
2025 Q1	$339K	Buy	212,003 +103,339	+95%	+$308K	﹤0.01%	931
2024 Q4	$391K	Buy	+108,664	New	+$540K	0.01%	900
2024 Q2	$600K	Buy	129,801 +78,436	+153%	+$468K	0.01%	650
2024 Q1	$420K	Buy	+51,365	New	+$398K	0.02%	498
2023 Q4	–	Sell	-17,572	Closed	-$32.7K	–	115
2023 Q3	$32.7K	Hold	17,572	–	–	﹤0.01%	355
2023 Q2	$48.3K	Hold	17,572	–	–	﹤0.01%	623
2023 Q1	$55.2K	Sell	17,572 -14,924	-46%	-$87.9K	﹤0.01%	922
2022 Q4	$192K	Buy	+32,496	New	+$269K	﹤0.01%	1074

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Susquehanna Fundamental Investments's CCCC Position: Q2 2026 in Review

Susquehanna Fundamental Investments opened a new position in C4 Therapeutics (CCCC) in Q2 2026: 18,800 shares worth $87.8K. The stake represents ﹤0.01% of the portfolio and ranks #725 among its holdings. This is a return to the name: Susquehanna Fundamental Investments previously reported a position in CCCC as recently as Q4 2025.

Susquehanna Fundamental Investments first reported a position in CCCC in Q4 2022 and has held it in 12 quarters since. The position peaked at $600K in Q2 2024. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

Susquehanna Fundamental Investments held 18,800 shares of C4 Therapeutics worth $87.8K as of Q2 2026.
C4 Therapeutics was a new Susquehanna Fundamental Investments position in Q2 2026.
C4 Therapeutics made up ﹤0.01% of Susquehanna Fundamental Investments's portfolio in Q2 2026, its #725 holding.
Susquehanna Fundamental Investments first reported a position in C4 Therapeutics in Q4 2022 and has held it in 12 quarters since.
Susquehanna Fundamental Investments's C4 Therapeutics position peaked at $600K in Q2 2024.
147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2026, filed 14 Aug 2026.